Exenatide (Byetta), a 39-amino acid synthetic GLP-1R agonist with longer biological activity than GLP-1, was approved by the FDA in 2005 as adjunctive therapy to improve glycemic control in patients with type 2 diabetes. Here, GLP1R is linked to type 2 diabetes mellitus.